| Předmět: |
|
| Zdroj: |
Respiratory Therapeutics Week; 8/30/2024, p1737-1737, 1p |
| Abstrakt: |
The article focuses on the long-term outcomes of the TROG 13.01 SAFRON II randomized trial comparing single- versus multifraction stereotactic ablative body radiotherapy (SABR) for pulmonary oligometastases. Topics include the safety and efficacy comparison between treatment arms, survival outcomes over a 5.4-year follow-up, and the cost-effectiveness of single-fraction SABR. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
